Plasma growth hormone
A majority of idiopathic pituitary dwarfs are thought to have defects in the hypothalamus, resulting in a lack of growth hormone releasing factor (GRF) synthesis or secretion (Kaplan 1975) . The hypothesis has been tested by several research groups (Borges et al., 1983; Grossman et al., 1983; Takano et al., 1984a) (Yoshimoto et al., 1975; Reitano et al., 1975; Hoffman and Crowley 1982) , similar repetitive administrations of hpGRF-44 may induce plasma GH responses in these non-responding pituitary dwarfs.
With the availability of large quantities of synthetic material, we have carried out such a study to investigate whether repetitive administrations of hpGRF-44 by im or iv infusion would induce plasma GH responses in patients with pituitary dwarfism who did not respond to a single iv bolus injection of the peptide.
Materials and Methods
Human subjects Fifteen patients with pituitary dwarfism were chosen for this study. Eleven of them were diagnosed as idiopathic GH deficiency while the remaining four were secondary to hypothalamopituitary tumors (subjects 12 and 13 have a craniopharyngioma 14 and 15 have an ectopic pinealoma). The clinical data on the 15 patients are summarized in Table 1 . The diagnosis of GH deficiency was established by failure of peak plasma GH to rise above 5ng/ml after insulininduced hypoglycemia (ITT) (Roth et al., 1963 ), glucagon-propranolol (Parks et al., 1973 , and/or L-dopa (Mims et al., 1973) tests. All of the 15 patients have been treated with hGH for periods ranging from 3 months to 7 years as well as medicated with the appropriate replacement therapy for other deficient pituitary hormones. They had no detectable hGH antibody in their plasma resulting from the hGH treatment.
Informed consent was obtained from each patient and/or the parents, and the study protocol was approved by our Department Review Committee at Tokyo Women's Medical College. 3, 5, 6, 7, 8, 9, 10, 11 and 13 from Kabi (Stockholm, Sweden) was used as label and standard. The intra-and inter-assay coefficients of variation were 6.6% and 8.0%, respectively. The minimal detectable plasma GH level was 1.0ng/ml. patients who responded to a single iv bolus injection of hpGRF-44). Each patient received an iv infusion of hpGRF-44 at a dosage of 2.5,tegimin for 90 min for three to six consecutive days. Inserted parentheses indicate the integrated area under the curve of plasma GH in ng/ml-h during iv infusion of hpGRF-44. The number at the left upper corner of each panel corresponds to the patient shown in Table 1. these patients before and after the repetitive im injections.
All patients showed plasma GH responses after the repeated im administrations; their peak plasma GH levels ranged between 5.8 and 10.6ng/ml (Fig. 1) . In particular, two of these patients (No.3 and 4) who had not responded to a single iv bolus injection of hpGRF-44, had their maximal plasma GH values increased from 4.1 to 10.6 and from 4.4 to 7.4ng/ml, before and after the treatment, respectively. Likewise, the integrated area under the plasma GH curve increased from 4.8 to 12.0 and from 5.1 to 7.9ng/ml-h, respectively.
Response of plasma GH to repetitive iv infusion of hpGRF-44
Ten patients (No.1, 3, 5, 6, 7, 8, 9, 10, 11 and 13) three to six consecutive days (Fig. 2) . In four patients (No.1, 3, 5 and 6), greater GH responses to hpGRF-44 were induced by repetitive iv infusions of hpGRF-44 on the days following the first day of infusion ( Fig. 2A and 2B ), i. e. the peak plasma GH increased from 4.4 to 7.5, from 3.4 to 7.5, from 3.3 to 9.9, and from 3.8 to 12.5ng/ ml, on the first day versus the day when the greatest response was obtained respectively, and likewise the integrated area under the GH curve increased. In addition, one patient (No.9) showed a minute GH response to hpGRF-44 on the day following the first day of infusion, i. e. the peak plasma GH level rose from 2.6 to 4.9ng/ ml, and the integrated GH increased from 2.6 to 5.4ng/ml-h, on the first versus the third day of infusion (Fig. 2A) . However, in the remaining five patients (No.7, 8, 10, 11 and 13), plasma GH responsiveness did not change significantly during repetitive iv infusion of hpGRF-44 ( Fig. 2A) Thus, repetitive administrations of hpGRF-44 can induce plasma GH response in some idiopathic GH deficient patients who do not respond to a single iv bolus of the peptide. This finding is similar to the induction of plasma gonadotropin response after repetitive administrations of GnRH in patients with idiopathic hypogonadotropic hypogonadism (Yoshimoto et al., 1975; Reitano et al., 1975; Hoffman and Drowley 1982) .
The remaining four idiopathic pituitary dwarfs, who did not have a plasma GH response to the repeated administrations of hpGRF-44, may not all have intrinsic pituitary diseases. They had normal PRL responses to TRH, and delayed or normal TSH responses to TRH, and some of them had normal LH and FSH responses to GnRH, as shown in Table 1 . In addition, they developed hypothyroidism during hGH therapy. These endocrinological data indicate that they may not have defects in the pituitary. Therefore, the frequency and duration of administration of hpGRF-44 in our present study may not be sufficient to induce plasma GH response to the peptide in these four patients.
The other possible reason for them to fail to respond to repeated administrations of hpGRF-44 is the dose of hpGRF-44.
However, there was no correlation between the dose per kg used and the GH responses in each experiment in this study. Furthermore, it has been reported that somatomedin inhibits pituitary GH secretion by stimulating somatostatin secretion (Berelowitz et al., 1981) and blunting the response to GRF (Brazeau et al., 1982) . Therefore, their plasma somatomedin-C values may affect plasma GH responses to hpGRF-44.
In the present study, the patients had been off hGH therapy for a very short time (2 to 4 days) and their plasma somatomedin-C levels varied from 0.1 to 1.0 U/ml (data not shown). However, there was no relationship between their plasma somatomedin-C values and their GH responses to hpGRF-44. In addition long term treatment of hGH may cause atrophy of somatotrophs and then may affect hGH responses to hGRF.
But, in the present study we could not find the relationship between plasma GH responses to hpGRF-44 and duration of hGH treatment.
In the four GH deficient patients with organic lesions of the hypothalamus or pituitary, three (No.12, 14 and 15) responded to a single iv bolus injection of hpGRF-44. They also responded to the peptide after repetitive im injections of hpGRF-44 for five days, but these responses were not different from those before treatment. One patient (No.13), who did not respond at all after repetitive administrations of hpGRF-44, had a craniopharyngioma that was resected and irradiated before he participated in this study. His clinical profile presented a case of panhypopituitarism because he showed no pituitary hormone responses to GnRH, TRH, and insulin induced hypoglycemia.
We have previously shown that the majority of normal children with short stature have a peak plasma GH level above 20ng/ ml in response to a single iv bolus injection of hpGRF-44 (Takano et al., 1984b) . In this study, the maximal values of plasma GH induced by hpGRF-44 never rose above 20ng/ml in the pituitary dwarfs even after repeated treatment with the peptide. To determine whether GH responses to hpGRF-44 are induced in pituitary dwarfs to the same degree as in normal children, further study will be required.
